Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Kasun Kariyawasam hailed as bridge engineering rising star

A Gates Cambridge Scholar has been selected as one of 17 winners of the New Civil Engineer Bridges Awards 2025 by New Civil Engineer. Kasun Kariyawasam won the Bridge Engineer […]

Why cancer needs to be reframed, not renamed

Cancer needs to be reframed rather than renamed in order to reduce overtreatment, a Gates Cambridge Scholar argues in a new article. In The Power of the ‘C’ word’, published by […]

Uncovering the complex layers of history in the Middle East

Noam Perl Treves’ PhD will explore Muslim-Jewish relations in 20th century Yemen, focusing on the country’s rural regions. The history of Yemeni Jews has been shaped by tribality, geographical dispersion […]

Climate diplomacy and just transitions: who pays for the future?

Three Gates Cambridge Scholars discussed climate diplomacy and just transition at a 25th anniversary Gates Cambridge Weekend on Saturday. The panel, chaired by Gates Cambridge Provost Eilis Ferran, covered the […]